MangoRx Launches Oral Tirzepatide (TRIM) for Weight Loss
Key Insights
MangoRx has introduced TRIM, an oral dissolvable Tirzepatide tablet, priced at $399 per month, offering a convenient alternative to injectable weight loss therapies.
Clinical trials demonstrated that Tirzepatide can achieve significant weight loss, with participants experiencing up to 20% reduction in 72 weeks and 25% in 88 weeks.
The launch positions MangoRx to capitalize on the expanding GLP-1 market, projected to grow to $157.5 billion by 2035, driven by the obesity (search) treatment segment.
MangoRx (NASDAQ: MGRX) has launched TRIM, a compounded oral dissolvable Tirzepatide tablet, offering a new approach to weight loss management. Priced at $399 per month, TRIM provides a convenient, non-invasive alternative to injectable therapies, potentially improving patient adherence and expanding access to treatment.
Tirzepatide, a dual GIP and GLP-1 receptor (search) agonist, has demonstrated substantial weight loss efficacy in clinical trials. Participants in these trials achieved weight reductions of 15-20% over 72 weeks and up to 25% over 88 weeks, highlighting its potential as a long-term weight management solution. The SURMOUNT-1 trial, a phase 3 study, further validated these findings, showing significant weight loss in obese individuals.
Convenient Oral Formulation
TRIM's oral formulation eliminates the need for injections, addressing a key barrier to entry for many patients. This ease of administration may lead to better adherence and broader adoption, according to MangoRx CEO Jacob Cohen. "We are excited to bring TRIM to market, offering consumers a cutting-edge, oral alternative to conventional weight loss injections," Cohen stated.
Market Opportunity
The launch of TRIM strategically positions MangoRx within the rapidly expanding GLP-1 market. A study by Roots Analysis projects the global GLP-1 market to grow from $49.3 billion in 2024 to $157.5 billion by 2035, with obesity (search) treatments expected to dominate. MangoRx now offers both Tirzepatide (TRIM) and Semaglutide (SLIM) options through its telemedicine platform, providing patients with a choice of advanced GLP-1 receptor (search) agonists tailored to their individual needs.
Clinical Evidence
Clinical trials have underscored Tirzepatide's effectiveness in promoting significant and sustained weight loss. The SURMOUNT-4 trial, for example, showed that patients experienced up to a 25% total weight reduction after 88 weeks of treatment, with nearly 90% maintaining at least 80% of their initial weight loss. These results highlight the potential for long-term weight management with Tirzepatide.
Future Outlook
While the introduction of TRIM represents a significant step forward for MangoRx, the company acknowledges the importance of ongoing innovation and adaptation to meet evolving patient needs. The telemedicine platform ensures access to safe and reliable options, but the company's ability to navigate regulatory hurdles and compete with established pharmaceutical giants will be critical for sustained success.